Significant Update Regarding Obesity Management Medications

On 11/6/2025, the White House announced significant changes to pricing for medications used to treat obesity.

There are 4 pathways for patient access:

1. TrumpRx.gov (Launching Jan 2026) This will be a government-run, direct-to-consumer cash-pay website.
- Injectables (Wegovy/Zepbound): Starting at ~$350/month, trending down to $245/month over two years
- Oral GLP-1s (once approved): Starting doses will be priced around $145/month

2. Medicare Coverage (Starting Mid-2026) For the first time in history, Medicare will cover medications for obesity. The current pathway is only through obesity-related comorbidities: OSA, CVD, DM2 and MASH (which will likely continue to be covered).
- Patients will pay a $50/month co-pay.
To qualify, patients need to meet one of the three following criteria:
- BMI >27 with prediabetes or established cardiovascular disease
- BMI >30 with uncontrolled hypertension, kidney disease, or heart failure
- BMI >35

3. Medicaid Coverage (It is unclear how this may change for MN)
- States will have the option to opt in (or out) for the $245/month for GLP-1s for all covered uses.

4. LillyDirect (New Prices Coming Soon)
- As a separate cash-pay option, Lilly has lowered its price for Zepbound to $299/month for 2.5mg (up to $449/month for higher doses). It is unclear if the 45-day ordering rule will still apply.
-Zepbound will be available in a new multi-dose pen (Awaiting FDA approval)